Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

TO ALL: this is our last message on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
MedResCollab Member Profile
 
Followed By 2
Posts 211
Boards Moderated 0
Alias Born 01/18/19
160x600 placeholder
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Present... GlobeNewswire Inc. - 5/4/2021 7:00:00 AM
Amarin reports decline in Q1 revenue ahead of European launch of VAZKEPA Seeking Alpha - 4/29/2021 7:31:32 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/29/2021 6:36:55 AM
Amarin EPS beats by $0.07, misses on revenue Seeking Alpha - 4/29/2021 6:16:54 AM
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 4/29/2021 6:10:00 AM
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel GlobeNewswire Inc. - 4/29/2021 6:00:00 AM
Amarin Q1 2021 Earnings Preview Seeking Alpha - 4/28/2021 1:06:54 PM
UK approves Amarin's Vazkepa for cardiovascular risk reduction Seeking Alpha - 4/22/2021 11:22:31 AM
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agenc... GlobeNewswire Inc. - 4/22/2021 10:53:02 AM
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 GlobeNewswire Inc. - 4/20/2021 6:05:00 AM
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Present... GlobeNewswire Inc. - 4/17/2021 9:50:00 AM
Amarin: Could the New CEO Help Vazkepa’s European Push? TipRanks - 4/13/2021 3:05:37 PM
Amarin falls as new CEO may mean M&A less likely in the near term Seeking Alpha - 4/13/2021 8:08:18 AM
Amarin CEO John Thero to retire Seeking Alpha - 4/12/2021 4:36:21 PM
Amarin Announces CEO Succession Plan GlobeNewswire Inc. - 4/12/2021 4:30:00 PM
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular... GlobeNewswire Inc. - 4/6/2021 6:05:00 AM
Amarin wins EU approval for icosapent ethyl to treat cardiovascular patients Seeking Alpha - 3/30/2021 7:42:41 AM
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk GlobeNewswire Inc. - 3/30/2021 6:24:23 AM
Amarin announces clinical recommendations for Vascepa in Canada and Egypt Seeking Alpha - 3/29/2021 10:33:15 AM
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is R... GlobeNewswire Inc. - 3/29/2021 7:00:00 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
HLS Therapeutics highlights promising VASCEPA data analysis Seeking Alpha - 3/17/2021 11:55:39 AM
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in... GlobeNewswire Inc. - 3/17/2021 11:30:00 AM
Amarin Q4 results led by strong Vascepa sales Seeking Alpha - 2/25/2021 9:48:43 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 6:07:01 AM
MedResCollab   Friday, 07/12/19 10:54:42 AM
Re: jessellivermore post# 201191
Post # of 339101 
TO ALL: this is our last message on investorshub, as we have decided not to renew our IRP membership here. We are content to have created a backlog of posts that may be examined in the future.

Good luck to all, and we hope you seek the advice of a registered investment advisor on your exposure to risk in AMRN, and on hedging strategies.

Quote:
Sounds like you "get it"...It's going to take a whole lot more than a couple of patent breakdowns [to significantly impact Vascepa sales] --jesselivermore



Amarin insiders have never once said they can "control the supply," and any inferences that they can thwart generic producers are greatly exaggerated.

Consider the ability of GSK to "thwart generic cos" from producing and selling generic Lovaza. They couldn't, at all. Sales dropped 75% in under a year. You think tiny AMRN can? It is absolutely not that complex to produce high-purity ethyl ester EPA (high-purity rTG EPA is trickier, but DS industry handles it just fine). It's a tech that has been around since the 70s, refined and streamlined in the 80s, and commercially launched in 1990 with Epadel--almost 30 years ago.

Let's be realistic here. DRL and Hikma will have absolutely no problem undercutting and taking >95% of Amarin's sales, and >70% in the first year, even if that just comes down to the automatic script switch that occurs at every pharmacy (it is actually law that they do so). Even if the script is for "Vascepa," the pharmacy fills it with generic Vascepa. If the patient protests, too bad.

That is the reality facing every company that seeks to stifle generic competition. There are antitrust laws in place to protect against it. The system is set up to support lower cost drugs. As it should be.

Not to mention, the court's ruling is coming soon--late Jan/early Feb. Amarin won't have any time to ramp up enough to even draw out the ultimate ruin of their business model.

Regards,
-MRC



...
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences